Pegylated interferon-alpha2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers

Alimentary Pharmacology & Therapeutics
G BarrilV Carreño

Abstract

Therapeutics in end-stage renal disease (ESRD) patients undergoing haemodialysis (HD) has to consider potential drug clearance during the dialysis procedure. Pegylated interferon-alpha (PEG-IFN-alpha), a middle-size protein drug active against viral hepatitis, allows convenient once-weekly dosing due to prolonged plasma half-life. To investigate the impact of permeability and dialyser pore size on PEG-IFN-alpha blood levels during experimental HD. Polymethylmetacrylate (PMMA) membrane 1.6 m2 dialysers with three different permeabilities/pore sizes were selected. A 40 kDa PEG-IFN-alpha2a (PEGASYS) was not cleared (< 5%) through low-flux/small pore size (25 A;B3A) and high-flux/middle-large pore size (60 A;BKP) dialysers, and was partially (approximately 15%) through intermediate permeability/large pore size (100 A;BKF) dialysers. In contrast, unmodified 17 kDa IFN-alpha2a(Roferon-A) was removed (65%-95%) through BKP or BKF, but not B3A, PMMA dialysers. Moreover, 12 kDa PEG-IFN-alpha2b(PegIntron) was cleared (40%-80%) through PMMA dialysers with pore sizes > or = 60 angstroms. When B3A or BKP were replaced every hour PEG-IFN-alpha2a plasma levels remained constant throughout three experimental-HD-sessions, but PEG-IFN-alpha2b was...Continue Reading

References

Mar 1, 1979·The American Journal of Physiology·L J Mullins
Nov 1, 1990·Clinical Pharmacokinetics·R J Wills
May 8, 1999·British Journal of Clinical Pharmacology·E ChatelutP Canal
Aug 8, 2001·Seminars in Dialysis·L W HendersonA K Cheung
Aug 21, 2001·Clinical Pharmacokinetics·J M HarrisM Modi
Mar 5, 2002·Seminars in Dialysis·Raymond VanholderGerrit Lesaffer
Mar 20, 2002·Cerebrovascular Diseases·David W Desmond
May 2, 2002·Kidney International. Supplement·Claudio RoncoGiuseppe La Greca
Jun 26, 2002·Artificial Organs·Sunny ElootPascal Verdonck
Jul 9, 2002·Seminars in Dialysis·William R Clark, Dayong Gao

❮ Previous
Next ❯

Citations

Jan 29, 2011·Leukemia·S AnguilleE L J M Smits
Apr 21, 2007·Kidney & Blood Pressure Research·Petar Kes, Nikolina Basic-Jukic
Apr 12, 2014·Clinical Pharmacokinetics·Clara T M M de KanterDavid M Burger
Jun 12, 2013·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Po-Lin TsengTsung-Hui Hu
Apr 6, 2006·Liver International : Official Journal of the International Association for the Study of the Liver·Cristina M RochaMaria Lucia G Ferraz
Jul 15, 2011·International Journal of Nephrology·Marco CarboneJames Neuberger
Jul 30, 2008·Journal of Hepatology·Paul Martin, Fabrizio Fabrizi
Jan 9, 2009·Clinical Journal of the American Society of Nephrology : CJASN·Norberto PericoGiuseppe Remuzzi
Oct 1, 2008·The International Journal of Artificial Organs·C MolinoC Longhini
Feb 21, 2008·The International Journal of Artificial Organs·A MangiaUNKNOWN Italian Association for The Study of The Liver (A.I.S.F)
Apr 25, 2008·The International Journal of Artificial Organs·D CarrieroD T Dieterich
Jul 19, 2005·Clinics in Liver Disease·Fabrizio FabriziPaul Martin
Feb 4, 2010·Clinics in Liver Disease·Fabrizio Fabrizi, Paul Martin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.